BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

8 articles for R Lattmann

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
 
Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid seriesEBI
TBA
Novel scaffold for cathepsin K inhibitors.EBI
Novartis Institutes For Biomedical Research
Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension.EBI
Novartis Institutes of Biomedical Research (NIBR)
SHMT inhibitorsBDB
The Trustees of Princeton University
Antidiabetic bicyclic compoundsBDB
Merch Sharp & Dohne Corp. Rahway
Pyrimidines as sodium channel blockersBDB
TBA
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.BDB
Glaxosmithkline
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.BDB
Astrazeneca